Kadono, Yoshifumi, et al. “Favorable Response of Pembrolizumab As Second-Line Therapy for Advanced Urothelial Carcinoma With Only Small Lesions to Not Be Considered Measurable by RECIST”. Urology Journal, vol. 19, no. 03, Dec. 2021, pp. 202-8, doi:10.22037/uj.v19i03.6652.